• 研究課題をさがす
  • 研究者をさがす
  • KAKENの使い方
  1. 課題ページに戻る

2016 年度 実績報告書

Development of a novel therapy for sickle cell disease by Nrf2 activation

研究課題

研究課題/領域番号 16H06639
研究機関東北大学

研究代表者

Keleku Nadine  東北大学, 医学系研究科, 産学官連携研究員 (40781761)

研究期間 (年度) 2016-08-26 – 2018-03-31
キーワードsickle cell disease / Nrf2 / Specific activation / oxidative stress
研究実績の概要

During the year 2016, we performed experiments using SCD:Keap1 F/F Tie1 Cre and SCD: Keap1 F/F LysM Cre mice in which Nrf2 activation is limited to endothelial cells and myeloid cells including macrophages, respectively. We confirmed the amelioration of inflammation and organ damages in both SCD:Keap1 F/F Tie1 Cre and SCD: Keap1 F/F LysM Cre mice compared with control (SCD: Keap1 F/F) mice, while experiments regarding oxidative stress are partially done and still going. Results of RNA-sequencing, which were done in place of Microarray assay to investigate the mechanism underlying the role of Nrf2 in SCD, show that endothelial specific activation of Nrf2 upregulated large range of genes such genes of heme metabolism (Hmox-1), phase I and II detoxification enzymes, antioxidants and others in the SCD:Keap1 F/F Tie1 Cre mice. In addition, we also performed imaging mass and CE-MS spectometry to study heme distribution as well as glutathione activity. Heme distribution in SCD:Keap1 LysM Cre mice was significantly lower than that in SCD:Keap1 Tie1 Cre mice, suggesting that Nrf2 activation in macrophages promotes heme degradation. To reproduce the results for SCD:Keap1 LysM Cre mice, further experiments are ongoing.

現在までの達成度 (区分)
現在までの達成度 (区分)

2: おおむね順調に進展している

理由

We have successfully completed the analysis with SCD: Keap1 F/F Tie1 Cre mice. The experiments using mice with specific activation of Nrf2 in macrophages are ongoing. These delays are due to few numbers of animals obtained from breeding. As we finished the analysis with SCD: Keap1 F/F Tie1 Cre mice, we will dedicate the breeding space to SCD:Keap1 LysM Cre mice.
The study in DRC of Congo was delay for reasons related to the delay in the acquiring of necessary approval documents. As these documents are being processed right now, we expect the study to be speed up as soon as possible.

今後の研究の推進方策

TThe 2017 research plan will be about:
I. Contribution of Nrf2 activation in macrophages to explain improvement of SCD
We will continue searching for major target genes of Nrf2 responsible for amelioration of SCD symptoms and analyzed the oxidative pattern in organs of SCD: Keap1 LysM Cre mice.
II. Submission of the paper for publication
III. Correlation between NRF2 expression and clinical history of human SCD patients in Congo. We are studying the correlation between NRF2 SNP (NRF2 expression levels) and clinical symptoms of SCD. We are going to collect SCD patients saliva for SNIP analysis and conduct informatics analysis using demographic data as well as clinical data (medication, pathological events). All these information, will determine the NRF2 contribution to improvement of SCD symptoms.

  • 研究成果

    (3件)

すべて 2017 2016

すべて 雑誌論文 (2件) (うち査読あり 2件) 学会発表 (1件)

  • [雑誌論文] Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation.2017

    • 著者名/発表者名
      Tsuchida K, Tsujita T, Hayashi M, Ojima A, Keleku-Lukwete N, Katsuoka F, Otsuki A, Kikuchi H, Oshima Y, Suzuki M, Yamamoto M.
    • 雑誌名

      Free Radic Biol Med

      巻: 103 ページ: 236-247

    • DOI

      10.1016/j.freeradbiomed.2016.12.041.

    • 査読あり
  • [雑誌論文] Overview of redox regulation by Keap1-Nrf2 system in toxicology and cancer.2016

    • 著者名/発表者名
      Suzuki M, Otsuki A, Keleku-Lukwete N, Yamamoto M.
    • 雑誌名

      Curr Opin in Toxicol

      巻: 1 ページ: 29-36

    • 査読あり
  • [学会発表] Insight mechanism underlying the importance of Nrf2 in sickle cell disease.2016

    • 著者名/発表者名
      Nadine Keleku-Lukwete、Harit Panda、長沼絵里子、鈴木未来子、山本雅之.
    • 学会等名
      第89回日本生化学会大会
    • 発表場所
      仙台国際センター, 仙台
    • 年月日
      2016-09-25 – 2016-09-27

URL: 

公開日: 2018-01-16  

サービス概要 検索マニュアル よくある質問 お知らせ 利用規程 科研費による研究の帰属

Powered by NII kakenhi